Literature DB >> 99132

Proton irradiation of choroidal melanomas. Preliminary results.

E S Gradoudas, M Goitein, A Koehler, I J Constable, M S Wagner, L Verhey, J Tepper, H D Suit, R J Brockhurst, R J Schneider, K N Johnson.   

Abstract

Choroidal malignant melanomas in nine patients were treated with proton beam irradiation at the Harvard Cyclotron Laboratory, Cambridge, Mass. Each patient received five proton beam treatments in eight to ten days, totalling 4,730 to 8,570 rads at the tumor. No complications occurred during the treatment or follow-up period, which, at the time of this writing, ranges from one to 24 months, with an average of 12 months. No further growth of the tumor has been observed in any patient. Different signs of tumor regression have been noted. Resolution of the serous retinal detachments that accompanied some tumors is the earliest finding. Pigment changes over the surface of the tumor and adjacent pigment epithelium is a usual initial tumor response. Fluorescein angiography initially showed decreased leakage of dye; later, destruction of the tumor's vasculature and elimination of fluorescein leakage became evident. Only large choroidal vessels remained patient. Ultrasonography revealed decreased height of the tumors postirradiation, and the radioactive phosphorus (32P) uptake test, repeated in one patient, turned negative on postirradiation measurements.

Entities:  

Mesh:

Year:  1978        PMID: 99132     DOI: 10.1001/archopht.1978.03910060217006

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  8 in total

1.  A randomized, controlled trial of varying radiation doses in the treatment of choroidal melanoma.

Authors:  E S Gragoudas
Journal:  Trans Am Ophthalmol Soc       Date:  1998

2.  Radiotherapy in ophthalmology : 2004 Jules Gonin lecture of the Retina Research Foundation.

Authors:  Leonidas Zografos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-07       Impact factor: 3.117

3.  Monte Carlo calculations and measurements of absorbed dose per monitor unit for the treatment of uveal melanoma with proton therapy.

Authors:  Nicholas Koch; Wayne D Newhauser; Uwe Titt; Dan Gombos; Kevin Coombes; George Starkschall
Journal:  Phys Med Biol       Date:  2008-02-25       Impact factor: 3.609

4.  Concurrent versus sequential application of ferromagnetic hyperthermia and 125I brachytherapy of melanoma in an animal model.

Authors:  W F Mieler
Journal:  Trans Am Ophthalmol Soc       Date:  1997

5.  Proton beam radiotherapy in the management of uveal melanoma: Clinical experience in Scotland.

Authors:  Samir Aziz; Alex Taylor; Andrzej McConnachie; Alex Kacperek; Ewan Kemp
Journal:  Clin Ophthalmol       Date:  2009-06-02

6.  Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma.

Authors:  Evangelos S Gragoudas; Anne Marie Lane; John Munzenrider; Kathleen M Egan; Wenjun Li
Journal:  Trans Am Ophthalmol Soc       Date:  2002

7.  Regression of posterior uveal malignant melanomas after cobalt plaque radiotherapy.

Authors:  J J Augsburger; B T McNeary; H von Below; J W Gamel; J A Shields; L W Brady; A M Markoe; J L Day
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

8.  Survival after primary enucleation for choroidal melanoma: changes induced by the introduction of conservative therapies.

Authors:  J Gambrelle; J D Grange; M Devouassoux Shisheboran; M Rivoire; L G Baggetto; B Jean-Louis; J Fleury; L Kodjikian
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-22       Impact factor: 3.535

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.